ADIL
NASDAQAdial Pharmaceuticals Inc
News · 26 weeks40+400%
2026-03-012026-08-23
Mix2190d
- SEC Filings8(38%)
- Insider8(38%)
- Other3(14%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company. The option award has an exercise price of $5.76 per share, the closing price of the Company’s common stock on August 19, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the
- SECSEC Form DEF 14A filed by Adial Pharmaceuticals IncDEF 14A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business UpdateCompleted acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor ("Ahr") agonist in development for ulcerative colitis, to its pipeline Closed initial $32 million tranche, including the conversion of notes, of an up to $64 million private placement from biotech specialist investors GLEN ALLEN, Va., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today provided a business update and reported its financial results for the 2026 second quarter ended June 30, 2026. "The acquisition of Azora Therapeutics and the concurrent financing mark an important inflection point for Adial
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Other Events8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECSEC Form PRE 14A filed by Adial Pharmaceuticals IncPRE 14A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAmendment: Adial Pharmaceuticals Inc filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- ANALYSTAlliance Global Partners initiated coverage on Adial Pharmaceuticals with a new price targetAlliance Global Partners initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $11.00
- INSIDERLarge owner Coastlands Capital Lp bought $8,691 worth of shares (3,233 units at $2.69) (SEC Form 4)4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERLarge owner Coastlands Capital Lp bought $32,638 worth of shares (11,753 units at $2.78) (SEC Form 4)4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERLarge owner Coastlands Capital Lp bought $65,000 worth of shares (25,000 units at $2.60) (SEC Form 4)4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERNew insider Coastlands Capital Lp claimed ownership of 348,322 shares (SEC Form 3)3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- PRAdial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE FinancingGLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. ("Azora"), which was previously announced by the Company on June 11, 2026. Additionally, the Company today announced the
- INSIDERChief Development Officer Davidson Matt was granted 297,491 shares and was granted 1,923 units of Series A Preferred Stock (SEC Form 4)4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 3 filed by new insider Davidson Matt3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 4 filed by Director Young Wendy B.4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 3 filed by new insider Young Wendy B.3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Leadership Update, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 - Azora's oral candidate, AT177, is a novel, colon‑targeted AhR agonist rationally engineered to have minimal systemic exposure and designed to mitigate safety concerns with systemically absorbed AhR agonists - $32 million in upfront financing with the potential to receive an additional $32 million under additional milestone tranches - Adial to host a conference call today, June 11, 2026 at 1pm ET GLEN ALLEN, Va. and LOS ANGELES, June 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceutica
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business UpdateGLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026. "We are very encouraged by the continued progress we have made in early 2026 to advance AD04 toward late-stage development, particularly in light of several important regulatory and strategic developments that we believe meaningfully strengthen our path forward," said Cary Claiborne, Chief Executive Officer of Adia
- SECSEC Form 10-Q filed by Adial Pharmaceuticals Inc10-Q - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045GLEN ALLEN, Va., April 29, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the filing of a new U.S. utility application with the United States Patent and Trade Office (USPTO) directed to AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Once the patent is granted, it is expected to protect Adial's core assets through at least 2045. The application
ADIL FAQ
7 questionsWhat does Adial Pharmaceuticals Inc do?
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.Where does ADIL stock trade?
Adial Pharmaceuticals Inc (ADIL) is listed on NASDAQ.What sector and industry is ADIL in?
Adial Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adial Pharmaceuticals Inc go public?
Adial Pharmaceuticals Inc (ADIL) completed its IPO in 2018.What are analysts saying about ADIL?
Adial Pharmaceuticals Inc has had 4 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $1100.00 price target on 2026-08-03. Recent price targets range from $500.00 to $1200.00.What companies are similar to ADIL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ADIL side-by-side with any of them on Quantisnow.How can I track ADIL on Quantisnow?
Quantisnow aggregates Adial Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADIL to receive live email and push alerts on every new disclosure.